Medtronic Continues To Run (RNA) Interference With Biotech Firm Alnylam
This article was originally published in The Gray Sheet
Executive Summary
Medtronic is upping its investment in biotech drug delivery by expanding its collaboration with Alnylam for development of an RNA-based treatment for Huntington's disease